This table summarises the latest information provided by companies regarding the prices at which they are currently offering antiretrovirals to resource-poor countries, and the terms of the offers.
Some of these offers are being made through the UNAIDS Accelerating Access Initiative; others are being offered through programmes established by the companies themselves.
We will update this table regularly as more information becomes available. Any information on prices of generic alternatives would be welcomed; despite repeated efforts over the past few weeks we have been unable to establish the prices offered by manufacturers of generic antiretrovirals.
Generic name
Brand name
Initials
Manufacturer
Discount price
Special provisions
Generic alternative
Lopinavir/ritonavir
Kaletra
N/a
Abbott
c.$1,000 per year
Africa
(available to private sector or company health plans and NGOs, as well as govts)
None
Ritonavir
Norvir
N/a
Abbott
c. $1,000
Africa
(available to private sector or company health plans and NGOs, as well as govts)
India
Saquinavir
Fortovase
N/a
Roche
c. $1300 if dosed once daily with ritonavir, or $2400 if dosed at 1200mg three times daily
Available to least developed nations at negotiable prices - Roche is seeking to offer the drug at cost and offer research grants to those providing clinical care
none
Indinavir
Crixivan
N/a
Merck
$600 per year
Africa
Romania
Haiti
Brazil
Available to NGOs and company health plans, as well as govts
efavirenz
Stocrin
N/a
Merck
$500 per year
Africa
Romania
Haiti
Brazil
Available to NGOs and company health plans, as well as govts
stavudine
Zerit
D4T
Bristol Myers Squibb
15 cents a day/$54 per year
Not available to private sector/company health plans
Thailand
Brazil
India
didanosine
Videx
ddI
Bristol Myers Squibb
80 cents per day
Not available to private sector/
company health plans
Not patented in Africa
Thailand Brazil
India
nevirapine
Viramune
Boehringer Ingelheim
Free as two doses for mother and infant treatment
$1.22 per day for adult dosing ($445 p.a)
Maternal/infant treatment free to all non-EU countries (also excludes USA, Canada, NZ, Australia, Japan, Switzerland, Norway, Iceland)
India: Cipla (Nevimune$340 p.a)
Zidovudine and lamivudine
Combivir
AZT and 3TC
Glaxo Smith Kline
$2 per day
Developing countries - govts, NGOs and workplace initiatives where suitable medical infrastructure exists, via UNAIDS
Accelerating Access Initiative
Brazil
India
Zidovudine
Retrovir
AZT
Glaxo Smith Kline
95% reduction on "average global price"
As above
Brazil
India
Abacavir
Ziagen
N/a
Glaxo Smith Kline
As above
As above
none
Lamivudine
Epivir
3TC
Glaxo Smith Kline
58 cents per day
As above
Brazil
India
zalcitabine
Hivid
ddC
Roche
Available at cost
Brazil